Lantheus Holdings' Tauklarify Approval: A Game Changer for Alzheimer's Imaging
Lantheus Holdings receives FDA approval for Tauklarify, enhancing its position in the Alzheimer's diagnostics market.
Capricor Therapeutics' Stock Soars 77%: What It Means for Investors
Capricor Therapeutics shares surged 77% after FDA agreed to review DMD drug data, signaling a turnaround for the biotech.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Analyzing Treasury Yield Movements Amid Geopolitical Tensions
As Treasury yields rise, geopolitical tensions and manufacturing data shape market landscapes.
Capricor Therapeutics: A High-Stakes Bet on FDA Decision
Capricor Therapeutics' stock surged 67% after-hours amidst anticipation of an FDA decision on deramiocel.
Mobix Labs Ventures into Critical Minerals: Strategic Acquisition Explained
Mobix Labs' strategic acquisition marks a pivotal shift into critical minerals, reshaping its market landscape.
Outlook Therapeutics Faces Investor Backlash Post-FDA Approval: A Cautionary Tale
Outlook Therapeutics (OTLK) faces investor backlash as capital raise impacts share prices despite FDA approval of LYTENA…
Cullinan Oncology's Path to FDA Approval: What Investors Need to Know
Cullinan Oncology's recent Phase 3 trial results signal a pivotal moment for investors as the company pursues FDA approv…
Rocket Lab's Strategic Move: Clearing Regulatory Hurdles in the Iridium Acquisition
Rocket Lab's acquisition of Iridium marks a pivotal shift towards integrated space infrastructure, impacting the broader…
Cullinan Oncology's Stock Surge: Analyzing the Impact of Phase 3 Trial Results
Cullinan Oncology's positive Phase 3 trial results could reshape its market position and attract significant investor in…
Neurocrine Biosciences (NBIX) Faces Regulatory Scrutiny After Safety Concerns: What Investors Should Know
Neurocrine Biosciences (NBIX) faces scrutiny from regulators following safety alarms, including seven patient deaths. He…
Definium Therapeutics (DFTX) Phase 3 Trial Success: A Potential Game Changer for Anxiety Treatment
Definium Therapeutics' successful Phase 3 trial results could reshape anxiety treatment and boost investor sentiment.